导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.50% | 1609/4773 |
| 近一周 | -1.56% | 2305/5465 |
| 近一月 | -2.19% | 1512/5421 |
| 近一季 | -4.57% | 1846/5231 |
| 近半年 | 0.21% | 1343/4920 |
| 近一年 | 9.13% | 1236/4394 |
| 近两年 | 52.31% | 1434/2954 |
| 近三年 | 37.77% | 823/2253 |
| 成立以来 | 47.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.65% 1898/4961 |
11.17% 2364/5312 |
- - |
- - |
| 2025 | 22.02% 2005/4813 |
0.89% 1745/3635 |
1.55% 2283/4076 |
14.95% 2855/4524 |
3.60% 654/4813 |
| 2024 | 17.10% 728/3463 |
5.88% 328/2808 |
-0.21% 703/3014 |
12.62% 2310/3129 |
-1.59% 1760/3463 |
| 2023 | -9.62% 1201/2656 |
3.24% 1232/2280 |
-3.40% 791/2385 |
-2.74% 738/2515 |
-6.81% 1933/2655 |
| 2022 | -24.62% 1235/2207 |
-13.47% 765/1919 |
4.31% 1025/2016 |
-13.77% 970/2113 |
-3.16% 1838/2208 |
| 2021 | -1.44% 799/1822 |
-4.09% 848/1255 |
6.37% 756/1330 |
-4.63% 725/1466 |
1.30% 969/1822 |
| 2020 | - - |
- - |
- - |
18.03% 91/1164 |
13.48% 358/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方沪深300增强C VS. 长安沪深300非周期A(740101) |